Nom du produit:6-chloro-3-iodo-1-tetrahydropyran-2-yl-pyrazolo[3,4-b]pyrazine
IUPAC Name:6-chloro-3-iodo-1-(oxan-2-yl)-1H-pyrazolo[3,4-b]pyrazine
- CAS:2215028-64-9
- Formule moléculaire:C10H10ClIN4O
- Pureté:95%+
- Numéro de catalogue:CM479274
- Poids moléculaire:364.57
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:2215028-64-9
- Formule moléculaire:C10H10ClIN4O
- Point de fusion:-
- Code SMILES:ClC1=CN=C2C(I)=NN(C3CCCCO3)C2=N1
- Densité:
- Numéro de catalogue:CM479274
- Poids moléculaire:364.57
- Point d'ébullition:
- N° Mdl:MFCD32220431
- Stockage:
Category Infos
- Pyrazolopyrazines
- The pyrazolopyrazine ring system is a very interesting class of heterocyclic compounds considered as important scaffolds for many effective bioactive agents with low toxicity, antioxidant, anticonvulsant, antiparasitic, anti-inflammatory, antiviral, antibacterial, anti- Fungal and analgesic activity.
Column Infos
- GDC-1971
- Protein tyrosine phosphatase SHP2 mediates RAS-driven MAPK signaling and has emerged in recent years as a target of interest in oncology, both for treating with a single agent and in combination with a KRAS inhibitor. GDC-1971 (formerly RLY-1971) is a SHP2 inhibitor currently in clinical trials in combination with KRAS G12C inhibitor divarasib (GDC-6036) for the treatment of solid tumors driven by a KRAS G12C mutation.